These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28143383)

  • 1. Overview.
    Prudhomme M
    Anticancer Agents Med Chem; 2017; 17(1):2. PubMed ID: 28143383
    [No Abstract]   [Full Text] [Related]  

  • 2. Preface.
    Prudhomme M
    Anticancer Agents Med Chem; 2017; 17(1):3. PubMed ID: 28143384
    [No Abstract]   [Full Text] [Related]  

  • 3. N-heterocyclic carbene metal complexes as bio-organometallic antimicrobial and anticancer drugs.
    Patil SA; Patil SA; Patil R; Keri RS; Budagumpi S; Balakrishna GR; Tacke M
    Future Med Chem; 2015; 7(10):1305-33. PubMed ID: 26144266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry.
    Thota S
    Mini Rev Med Chem; 2016; 16(10):771. PubMed ID: 27161007
    [No Abstract]   [Full Text] [Related]  

  • 5. Metal/N-heterocyclic carbene complexes: opportunities for the development of anticancer metallodrugs.
    Cisnetti F; Gautier A
    Angew Chem Int Ed Engl; 2013 Nov; 52(46):11976-8. PubMed ID: 24115500
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial (Thematic Issue Role of Heteroaromatics as Anticancer Agents).
    Kaur H
    Anticancer Agents Med Chem; 2016; 16(10):1204. PubMed ID: 27592681
    [No Abstract]   [Full Text] [Related]  

  • 7. Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs.
    Chang JY; Lu GL; Stevenson RJ; Brothers PJ; Clark GR; Botting KJ; Ferry DM; Tercel M; Wilson WR; Denny WA; Ware DC
    Inorg Chem; 2013 Jul; 52(13):7688-98. PubMed ID: 23773210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.
    Liu W; Gust R
    Chem Soc Rev; 2013 Jan; 42(2):755-73. PubMed ID: 23147001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The progresses in curcuminoids-based metal complexes: especially in cancer therapy.
    Zhang Y; Khan AR; Fu M; Zhai Y; Yu A; Zhai G
    Future Med Chem; 2019 May; 11(9):1035-1056. PubMed ID: 31140861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metal-containing drugs and novel coordination complexes in therapeutic anticancer applications--part II.
    Kostova I
    Anticancer Agents Med Chem; 2010 Jun; 10(5):352-3. PubMed ID: 20545617
    [No Abstract]   [Full Text] [Related]  

  • 11. Organometallic anticancer compounds.
    Gasser G; Ott I; Metzler-Nolte N
    J Med Chem; 2011 Jan; 54(1):3-25. PubMed ID: 21077686
    [No Abstract]   [Full Text] [Related]  

  • 12. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).
    Zhang Z; Wang H; Yan M; Wang H; Zhang C
    Mol Med Rep; 2017 Jan; 15(1):3-11. PubMed ID: 27959411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclometalated Ir(III) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy.
    Ye RR; Tan CP; He L; Chen MH; Ji LN; Mao ZW
    Chem Commun (Camb); 2014 Sep; 50(75):10945-8. PubMed ID: 25096019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer metallotherapeutics in preclinical development.
    Kaluderović GN; Paschke R
    Curr Med Chem; 2011; 18(31):4738-52. PubMed ID: 21919843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Generation of Anticancer Metallopharmaceuticals: Cancer Stem Cell-Active Inorganics.
    Laws K; Suntharalingam K
    Chembiochem; 2018 Nov; 19(21):2246-2253. PubMed ID: 30109911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons.
    Yan JJ; Chow AL; Leung CH; Sun RW; Ma DL; Che CM
    Chem Commun (Camb); 2010 Jun; 46(22):3893-5. PubMed ID: 20401423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network pharmacology for cancer drug discovery: are we there yet?
    Azmi AS
    Future Med Chem; 2012 May; 4(8):939-41. PubMed ID: 22650234
    [No Abstract]   [Full Text] [Related]  

  • 19. Precision cancer medicine: where to target?
    Yu Q; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1161-2. PubMed ID: 26388154
    [No Abstract]   [Full Text] [Related]  

  • 20. Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks.
    Petanidis S; Kioseoglou E; Salifoglou A
    Curr Med Chem; 2019; 26(4):607-623. PubMed ID: 29149832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.